Dr. Yansong Liu 刘岩松
Chief Physician, Associate Professor
Breast Surgery, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and comprehensive treatment of breast diseases, including breast-conserving surgery, modified radical mastectomy, sentinel lymph node biopsy, minimally invasive tumor removal, and systemic therapies for early to advanced breast cancer.
Dr. Liu has specialized in breast disease diagnosis and treatment since 2001. In 2002, Dr. Liu reported the first domestic 10-year long-term outcomes of breast-conserving therapy. Dr. Liu holds four patents, participated in two international collaborative projects, and received four provincial science and technology progress awards. Dr. Liu serves as deputy editor-in-chief of "Mastology".
Professional roles
- Chair, Breast Disease Branch, Shandong Health Promotion and Education Society
- Vice Chair, Breast MDT Branch, Shandong Research Hospital Association
- Chair, Youth Committee of Breast Expert Committee, Shandong Clinical Oncology Society
- Expert, Drug Evaluation Center, National Medical Products Administration
Name order: in Chinese the family name comes first (Liu Yansong). Papers usually list the name as Yansong Liu or Liu Y.
Selected publications
17 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Lett, 2022 (first author): Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629]. PubMed 35527117
- Cancer Lett, 2022 (first author): Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B. PubMed 35278612
- Biochem Biophys Res Commun, 2020 (senior author): Corrigendum to"Cortistatin protects against inflammatory airway diseases through curbing CCL2 and antagonizing NF-κB signaling pathway". PubMed 33012512
- Biochem Biophys Res Commun, 2020 (senior author): Cortistatin protects against inflammatory airway diseases through curbing CCL2 and antagonizing NF-κB signaling pathway. PubMed 32811643
- Biol Chem, 2020 (first author): Derlin-1 functions as a growth promoter in breast cancer. PubMed 31721721
- Onco Targets Ther, 2019 (first author): The overexpression of Rab9 promotes tumor progression regulated by XBP1 in breast cancer. PubMed 30881034
- Pathol Oncol Res, 2018 (first author): CKS1BP7, a Pseudogene of CKS1B, is Co-Amplified with IGF1R in Breast Cancers. PubMed 28439706
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion